Experiential Interventions for Externalizing Behavior: A Multilevel Meta-Analysis of Adolescents and Adults.

Int J Offender Ther Comp CriminolMay 6, 2026 (epub)
Clinical ResearchPsychiatry

Larissa M Hoogsteder, Maartje W Kapteijns, Hester L van der Veld et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated the effectiveness of experiential interventions in reducing externalizing behaviors among adolescents and adults, analyzing 39 studies with 2,323 participants. Results indicated a significant medium effect size of g = 0.66 for these interventions compared to controls. Notably, integrating cognitive-behavioral therapy (CBT) components enhanced outcomes, with a larger effect size of g = 0.83.

Key findings

  • Experiential interventions showed a medium effect size of g = 0.66 compared to control conditions.
  • Integrating CBT with experiential interventions resulted in a larger effect size of g = 0.83.
  • Responsive CBT demonstrated the strongest effect size of g = 1.04.
  • Treatment fidelity and active system involvement significantly moderated outcomes.

Why it matters

Understanding the effectiveness of experiential interventions combined with CBT is crucial for clinicians working with adolescents and adults exhibiting externalizing behaviors. These findings can inform treatment strategies aimed at reducing aggression and rule-breaking, ultimately improving patient outcomes.

Source

Published in Int J Offender Ther Comp Criminol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.